礼来将收购Kelonia Therapeutics以推进体内CAR-T细胞疗法的发展-动脉网

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

礼来等信源发布 2026-04-20 23:31



可切换为仅中文







Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary session

凯洛尼亚公司的主要项目KLN-1010是一种潜在的首创慢病毒体内CAR-T疗法，目前正处于治疗复发/难治性多发性骨髓瘤的I期临床阶段，其临床数据最近在2025年ASH年会全体会议上被重点展示。

Acquisition expands Lilly's genetic medicine capabilities with a novel in vivo gene delivery and integration technology that has potential for broad applicability

收购扩展了礼来公司的基因药物能力，新增了一种具有广泛适用潜力的新型体内基因递送与整合技术。

INDIANAPOLIS

印第安纳波利斯

and

和

BOSTON, Mass.

马萨诸塞州波士顿市

，

April 20, 2026

2026年4月20日

/PRNewswire/ --

Eli Lilly and Company

礼来公司

(NYSE: LLY) and

(NYSE: LLY) 和

Kelonia Therapeutics, Inc.

凯洛尼亚治疗公司

('Kelonia'), a clinical-stage biotechnology company pioneering

凯勒尼亚（Kelonia）是一家处于临床阶段的生物技术公司，致力于开创性研究

in vivo

体内

gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.

基因递送，今天宣布了礼来公司收购凯洛尼亚的最终协议。

Kelonia has developed a proprietary

凯洛尼亚开发了一种专有的

in vivo

体内

gene placement system (iGPS

基因放置系统 (iGPS)

) that uses specially engineered lentiviral-based particles designed to efficiently and selectively enter T-cells inside the body, allowing the patient's own body to generate chimeric antigen receptor T-cell (CAR-T) therapies that can treat underlying disease. Kelonia's lead program, KLN-1010, is an investigational, one-time intravenous gene therapy that generates anti-B-cell maturation antigen (BCMA) CAR-T cells, targeting the BCMA protein expressed on the surface of multiple myeloma cells.

一种利用特殊工程改造的慢病毒颗粒的方法，旨在高效且选择性地进入体内的T细胞，使患者自身身体能够生成嵌合抗原受体T细胞（CAR-T）疗法以治疗基础疾病。Kelonia的主导项目KLN-1010是一种研究性的一次性静脉基因疗法，可生成抗B细胞成熟抗原（BCMA）的CAR-T细胞，靶向多发性骨髓瘤细胞表面表达的BCMA蛋白。

Encouraging early clinical results were presented in the plenary session of the 2025 .

2025年全体会议展示了鼓舞人心的早期临床结果。

American Society of Hematology

美国血液学会

Annual Meeting, providing initial clinical validation and demonstrated promising tolerability. KLN-1010 could represent a transformative advance in the treatment of multiple myeloma by eliminating the complexities of

年度会议提供了初步的临床验证，并展示了良好的耐受性。KLN-1010可能通过消除复杂性，代表了多发性骨髓瘤治疗中的革命性进展。

ex vivo

体外

patient-specific cell therapy manufacturing, and pre-administration chemotherapy.

患者特异性细胞治疗制造，以及预处理化疗。

'Autologous CAR-T therapies have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them. Kelonia's

“自体CAR-T疗法已显著改善了各种癌症患者的预后，但重大的生产、安全性和可及性障碍意味着只有少数符合条件的患者实际接受了这些治疗。Kelonia的

in vivo

体内

platform has the potential to change that by delivering rapid, durable responses in a far simpler, off-the-shelf format,' said

该平台有潜力通过以更简单、现成的格式提供快速、持久的响应来改变这一状况，

Jacob Van Naarden

雅各布·范·纳登

, executive vice president and president of Lilly Oncology and head of corporate business development. 'The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform. We look forward to working together with the Kelonia team to rapidly advance KLN-1010 to address patient need and recognize the full potential of their platform in other conditions where patients may benefit.'.

，执行副总裁兼礼来肿瘤事业部总裁以及公司业务发展主管。“KLN-1010 的早期临床数据非常令人鼓舞，这不仅是多发性骨髓瘤患者的潜在进步，也是对 Kelonia 平台概念的有力验证。我们期待与 Kelonia 团队紧密合作，快速推进 KLN-1010 的研发以满足患者需求，并充分释放其平台在其他可能使患者受益的疾病领域的潜力。”

'Kelonia's leadership in advancing the immense promise of

'Kelonia在推进巨大的前景方面的领导地位

in vivo

体内

cell therapy is unmatched, extending its reach and impact beyond the traditional boundaries of personalized medicine,' said

细胞疗法是无与伦比的，其影响力和覆盖范围超越了个性化医疗的传统界限。”

Kevin Friedman

凯文·弗里德曼

, Ph.D., chief executive officer of Kelonia. 'We have demonstrated the ability to achieve deep multiple myeloma remissions with significantly reduced complexity and cost relative to

，凯洛尼亚首席执行官，博士表示：“我们已经证明，与相对复杂且昂贵的方法相比，能够以显著降低的复杂性和成本实现多发性骨髓瘤的深度缓解。

ex vivo

体外

CAR T-cell approaches. In combination with Lilly's strengths, our

CAR T细胞方法。结合礼来公司的优势，我们的

in vivo

体内

iGPS platform is positioned to broaden the reach of cell therapy beyond the current CAR-T landscape in hematologic malignancies and to transform treatment across a far wider range of cancers and other serious diseases. It's been a privilege continuing the journey started by

iGPS平台旨在拓宽细胞疗法在血液系统恶性肿瘤中目前CAR-T领域的应用范围，并彻底改变更广泛癌症及其他严重疾病的治疗方式。能够继续这一旅程，我感到非常荣幸。

Michael Birnbaum

迈克尔·伯恩鲍姆

and the

和

Venrock

文洛克创投

team. I am deeply grateful to our employees, partners, and investigators, and most importantly, the patients who make this progress possible.'

团队。我深深感谢我们的员工、合作伙伴和研究者，最重要的是，感谢那些使这一进展成为可能的患者。’

Under the terms of the agreement, Lilly will acquire Kelonia, and Kelonia shareholders will receive up to

根据协议条款，礼来公司将收购Kelonia公司，Kelonia的股东将获得高达

$7.00 billion

70亿美元

in cash, inclusive of an upfront payment of

现金支付，包括首付款

$3.25 billion

32.5亿美元

, and subsequent payments upon achievement of certain clinical, regulatory and commercial milestones.

，并在达成某些临床、监管和商业里程碑后进行后续付款。

The transaction is subject to customary closing conditions, including customary regulatory approvals, and is expected to close in the second half of 2026. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing.

该交易需满足惯例的交割条件，包括惯例的监管批准，预计将于2026年下半年完成。礼来公司将在交割时根据公认会计原则（GAAP）确定此项交易的会计处理方法。

This transaction will thereafter be reflected in Lilly's financial results and financial guidance..

此项交易此后将反映在礼来的财务业绩和财务指引中。

For

为了

Lilly, Kirkland & Ellis LLP

莉莉，柯克兰和埃利斯律师事务所

is acting as legal counsel. For Kelonia,

担任法律顾问。对于凯隆尼亚，

Jefferies LLC

杰富瑞有限责任公司

is acting as financial advisor, and

担任财务顾问，并且

Goodwin Procter LLP

古德温·普罗克特律师事务所

is acting as legal counsel.

担任法律顾问。

About Kelonia Therapeutics

关于凯洛尼亚治疗公司

Kelonia Therapeutics is a clinical-stage biotechnology company pioneering a new wave of genetic medicines using its

凯勒尼亚治疗公司是一家临床阶段的生物技术公司，利用其技术开创了一波新的基因药物浪潮。

在

vivo

维沃

gene placement system (iGPS

基因放置系统 (iGPS)

). Kelonia's elegant, cutting-edge

). 凯洛尼亚的优雅、尖端科技

在

vivo

维沃

gene delivery technology uses an advanced lentiviral vector particle harboring envelope modification to improve

基因递送技术使用带有包膜修饰的先进慢病毒载体颗粒来改进

在

vivo

维沃

gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery. Kelonia is building a pipeline of genetic medicines across a range of diseases, with the bold goal of making CAR-T cell therapies accessible to every patient in need, when and where they need them. Kelonia's lead candidate, KLN-1010, is an .

基因转移效率和趋向性分子，以促进组织特异性递送。Kelonia 正在建立一个涵盖多种疾病的基因药物管线，其大胆的目标是让每位有需要的患者都能在需要的时间和地点获得 CAR-T 细胞疗法。Kelonia 的主要候选药物 KLN-1010 是一种。

in vivo

体内

anti-BCMA CAR-T therapy for multiple myeloma being evaluated in a Phase 1 clinical trial. Kelonia was incubated and seed funded by

正在一项一期临床试验中评估针对多发性骨髓瘤的抗BCMA CAR-T疗法。Kelonia公司由

Venrock

文洛克创投

. For more information, please visit:

欲了解更多信息，请访问：

https://www.keloniatx.com/

。

About Lilly

关于礼来

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治疗手段，以改善世界各地人们的生活。近150年来，我们一直致力于开创改变生命的发现，如今我们的药物已帮助全球数千万人。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转变为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

每迈向更健康的世界一步，我们都受到一个目标的激励：让数百万人的生活更加美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药物可及且负担得起。欲了解更多信息，请访问。

Lilly.com

莉莉网

and

和

Lilly.com/news

Lilly.com/新闻

, or follow us on

，或者关注我们

Facebook

脸书

，

Instagram

, and

，以及

领英

. F-LLY

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Kelonia and Kelonia's product candidates for oncology, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization.

本新闻稿包含关于礼来收购Kelonia及其在肿瘤学领域的产品候选药物的好处的前瞻性陈述（该术语定义见1995年《私人证券诉讼改革法案》），并反映了礼来目前的信念和期望。然而，像任何此类行动一样，在实施收购以及药物研究、开发和商业化过程中存在重大风险和不确定性。

Among other things, there can be no guarantee that the acquisition will be consumed on the intended timeline or at all, that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release, or that the acquisition will yield commercially successful products.

其中，无法保证收购将按预期时间表完成或完全实现，无法保证礼来公司将实现收购的预期效益，无法保证收购将达成此发布中讨论的结果，也无法保证收购将产生商业上成功的产品。

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the .

有关这些可能导致实际结果与礼来公司预期不同的风险和其他不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的Form 10-K和Form 10-Q报告。

United States Securities and Exchange Commission

美国证券交易委员会

. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

除非法律要求，礼来公司没有义务更新前瞻性声明以反映本发布日期之后的事件。

Refer to:

参考：

Ashley Hennessey;

阿什利·亨尼西；

gentry_ashley_jo@lilly.com

; 317-416-4363 (Media)

；317-416-4363（媒体）